<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05091255</url>
  </required_header>
  <id_info>
    <org_study_id>CRYODESMO</org_study_id>
    <nct_id>NCT05091255</nct_id>
  </id_info>
  <brief_title>Cryotherapy in the Treatment of Desmoid Tumors</brief_title>
  <official_title>Cryotherapy in the Treatment of Desmoid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Desmoid tumor is a benign neoplasm with an unpredictable course and a high rate of local&#xD;
      recurrence if treated surgically. Therefore, over time the surgical approach has become&#xD;
      conservative, preferring simple observation or medical therapy in case of disease progression&#xD;
      through the use of hormonal therapy and low-dose chemotherapy. Since this neoplasm remains&#xD;
      benign, our study aims to avoid chemotherapy in patients usually young through the use of a&#xD;
      minimally invasive treatment such as cryotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response to treatment</measure>
    <time_frame>At baseline (time 0)</time_frame>
    <description>assessment of tumor response to treatment will be performed using the solid tumor response criteria</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Desmoid</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryotherapy</intervention_name>
    <description>The procedure involves general or peripheral anesthesia and percutaneous treatment under CT control with probes capable of forming ice spheres of up to 3 cm that will be used in sufficient number to treat the neoplasm completely.</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Extra-abdominal desmoid tumors (trunk and limbs), without limits related to gender.&#xD;
        Histologic diagnosis confirmed by the Pathologic Anatomy of our Institute. Desmoid tumor&#xD;
        progressing after at least two lines of appropriate medical therapy [including tamoxifen,&#xD;
        nonsteroidal anti-inflammatory drugs (NSAIDs), or chemotherapy], with functional symptoms&#xD;
        and/or pain; unresectable tumor or tumor amenable only to mutilating surgery deemed&#xD;
        inappropriate. Patients with stable disease, but with persistent functional disability or&#xD;
        tumor-induced pain not controlled by appropriate pain therapy, Other criteria of inclusion&#xD;
        are: age &gt;18 years; tumor deemed accessible for cryotherapy procedure by the interventional&#xD;
        radiologist (with 90% of the tumor treatable by a cryoablation procedure and with a&#xD;
        possible second cryoablation procedure if necessary and if scheduled at study entry);&#xD;
        measurable lesion (mRECIST 1.1) using contrast-enhanced MRI.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Desmoid tumors of the abdominal wall. Contraindication to the procedure by the&#xD;
        interventional radiologist in terms of tumor size, proximity to neurologic/vascular&#xD;
        structures that make the procedure risky; contraindication to any form of sedation;&#xD;
        contraindication to MRI or gadolinium injection [proven allergy, glomerular filtration rate&#xD;
        (GFR)&lt;30 mL/min, renal disease]; psychiatric disorders and adults under guardianship,&#xD;
        pregnancy or lactation, or under judicial guardianship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Costantino Errani, MD</last_name>
    <phone>051-6366</phone>
    <phone_ext>6103</phone_ext>
    <email>costantino.errani@ior.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Itituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Costantino Errani, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Kujak JL, Liu PT, Johnson GB, Callstrom MR. Early experience with percutaneous cryoablation of extra-abdominal desmoid tumors. Skeletal Radiol. 2010 Feb;39(2):175-82. doi: 10.1007/s00256-009-0801-z. Epub 2009 Sep 21.</citation>
    <PMID>19768644</PMID>
  </results_reference>
  <results_reference>
    <citation>Redifer Tremblay K, Lea WB, Neilson JC, King DM, Tutton SM. Percutaneous cryoablation for the treatment of extra-abdominal desmoid tumors. J Surg Oncol. 2019 Sep;120(3):366-375. doi: 10.1002/jso.25597. Epub 2019 Jun 24.</citation>
    <PMID>31236956</PMID>
  </results_reference>
  <results_reference>
    <citation>Schmitz JJ, Schmit GD, Atwell TD, Callstrom MR, Kurup AN, Weisbrod AJ, Morris JM. Percutaneous Cryoablation of Extraabdominal Desmoid Tumors: A 10-Year Experience. AJR Am J Roentgenol. 2016 Jul;207(1):190-5. doi: 10.2214/AJR.15.14391. Epub 2016 Apr 11.</citation>
    <PMID>27064168</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>desmoid tumor; cryotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromatosis, Aggressive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

